2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.13B.08 Enhanced Efficacy of Anlotinib in Small Cell Lung Cancer after Immune Checkpoint Inhibitor Exposure

Pdf Summary

This study evaluates the efficacy of anlotinib, an anti-angiogenic drug, as a third-line treatment for patients with extensive-stage small cell lung cancer (ES-SCLC) who were previously exposed to immune checkpoint inhibitors (ICIs). The retrospective analysis involved 59 patients: 39 who had prior ICI exposure and 20 who had not.<br /><br />The primary endpoints of the study were progression-free survival (PFS) and overall survival (OS), with secondary endpoints focused on safety and adverse events. The study found that the PFS for the ICI-exposed group reached 11 months, significantly longer than 4 months for the control group. Similarly, overall survival was 21 months for patients with prior ICI treatment, compared to 10 months for those without, suggesting a significant benefit from anlotinib post-ICI therapy.<br /><br />Adverse events (AEs) were reported with Grade 3 or higher in 15% of the treatment group and 17.9% of the control group, with proteinuria being the most common severe AE. Other documented adverse events include hypertension, fatigue, and liver dysfunction, mainly occurring at Grades 1 and 2, with a few at Grade 3 or 4.<br /><br />These findings suggest that previous exposure to ICIs may enhance the efficacy of anlotinib in patients with SCLC, potentially offering a new treatment pathway. However, further prospective studies are necessary to confirm these results and understand the mechanisms involved.<br /><br />Baseline characteristics of the study participants showed a median age of 64 years, predominantly male (94.9%). Most participants had an Eastern Cooperative Oncology Group (ECOG) performance status of 1.<br /><br />Anlotinib as a third-line therapy, particularly after ICI treatment, underscores a promising strategy in managing ES-SCLC, suggesting improved outcomes in terms of both progression and overall survival.

Asset Subtitle

Jianzhen Shan

Meta Tag

Speaker Jianzhen Shan

Topic Small Cell Lung Cancer and Neuroendocrine Tumors

Keywords

anlotinib

anti-angiogenic

third-line treatment

extensive-stage small cell lung cancer

immune checkpoint inhibitors

progression-free survival

overall survival

adverse events

retrospective analysis

ECOG performance status